Effects of ondansetron exposure during ICU stay on outcomes of critically ill patients with sepsis: a cohort study

Background Sepsis is a life-threatening disease with high morbidity and mortality, characterized by an inadequate systemic immune response to an initial stimulus. Whether the use of ondansetron (OND) during intensive care unit (ICU) stay is associated with the prognosis of sepsis patients remains unclear. Methods Critically ill patients with sepsis were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Multivariate logistic regression and Cox regression analyses were used to explore the association between OND use and clinical outcomes after adjusting for confounders. Kaplan-Meier survival curve was used for survival analysis. Propensity score matching (PSM) and subgroup analysis were performed to further confirm the results. Results The OND-medication group showed reduced in-hospital mortality, 28-day and 90-day mortalities. The OR for in-hospital mortality was 0.80 (0.64-0.99) and HRs for 28-day mortality and 90-day mortality were 0.77 (0.64-0.92) and 0.83 (0.70-0.98), respectively. After PSM, the clinical outcomes remained consistent. In-hospital mortality was lower in the OND-medication group (28.1% vs. 35.8%, P= 0.044), as well as 28-day mortality (23.4% vs. 32.1%, P=0.022) and 90-day mortality (27.4% vs. 35.8%, P=0.035). The protective effect of OND in sepsis patients was relatively robust, independent of age, septic shock, vasopressin and mechanical ventilation. Additionally, the OND users had longer lengths of stay in ICU (6.9(3.1-13.2) vs. 5.1(2.5-11.0), P = 0.026) while no statistical differences were found in lengths of stay in hospital (P = 0.333). Conclusion OND exposure might be associated with lower in-hospital, 28-day, and 90-day mortality rates in critically ill patients with sepsis. This study indicated that OND might help improve the prognosis of patients with sepsis.

[1]  J. Vincent.  Current sepsis therapeutics , 2022, EBioMedicine.

[2]  Huacai Zhang,et al.  Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options , 2022, Military Medical Research.

[3]  Chao Xiong,et al.  Early Postoperative Ondansetron Exposure is Associated with Reduced 90-Day Mortality in Patients Undergoing Cardiac Surgery , 2022, Frontiers in Surgery.

[4]  J. Vincent,et al.  Septic shock: incidence, mortality and hospital readmission rates in French intensive care units from 2014 to 2018. , 2022, Anaesthesia, critical care & pain medicine.

[5]  J. Kellum,et al.  Kidney and Mortality Outcomes Associated with Ondansetron in Critically Ill Patients , 2022, Journal of intensive care medicine.

[6]  Shi-Yu Zhou,et al.  Mediators of neutrophil–lymphocyte ratio in the relationship between ondansetron pre‐treatment and the mortality of ICU patients on mechanical ventilation: Causal mediation analysis from the MIMIC‐IV database , 2021, British journal of clinical pharmacology.

[7]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. , 2021, Critical care medicine.

[8]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[9]  K. Asehnoune,et al.  Circulating Treg cells expressing TNF receptor type 2 contributes to sepsis-induced immunosuppression in patients during sepsis shock. , 2021, The Journal of infectious diseases.

[10]  D. Mevorach,et al.  Apoptotic cell therapy for cytokine storm associated with acute severe sepsis , 2020, Cell Death & Disease.

[11]  A. Hayes,et al.  Tropisetron ameliorates cyclophosphamide-induced hemorrhagic cystitis in rats. , 2020, European journal of pharmacology.

[12]  Chuang Yuan,et al.  Ethyl pyruvate protects against sepsis-associated encephalopathy through inhibiting the NLRP3 inflammasome , 2020, Molecular medicine.

[13]  David McManus,et al.  Atrial Fibrillation Detection During Sepsis: Study on MIMIC III ICU Data , 2020, IEEE Journal of Biomedical and Health Informatics.

[14]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[15]  Zhiwei Huang,et al.  Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. , 2019, The American journal of emergency medicine.

[16]  S. Hernández-Díaz,et al.  Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations. , 2019, JAMA.

[17]  T. Billiar,et al.  Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsis‐Induced Liver Injury by Granisetron Generation in Mice , 2019, Hepatology.

[18]  Xinmei Huang,et al.  Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: interaction effect with disease severity—a retrospective study , 2019, BMJ Open.

[19]  J. Vincent,et al.  Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit , 2018, Open forum infectious diseases.

[20]  Neetu J. Jain,et al.  Diagnostic and Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Early and Late Phase of Sepsis , 2018, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[21]  J. Burke,et al.  Improving outcome of sepsis on the ward: introducing the ‘Sepsis Six’ bundle , 2018, Nursing in critical care.

[22]  Murat Gündüz,et al.  Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study , 2018, Critical Care.

[23]  M. Shankar-Hari,et al.  Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database , 2017, British journal of anaesthesia.

[24]  B. Wan,et al.  Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta‐analysis of Chinese and Indian patients☆,☆☆ , 2017, Journal of critical care.

[25]  T. Inomata,et al.  The 5-HT3 Receptor Antagonist Ondansetron Attenuates Pancreatic Injury in Cerulein-Induced Acute Pancreatitis Model , 2017, Inflammation.

[26]  A. Kovac.  Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting , 2016, Drugs.

[27]  Kenjiro Matsumoto,et al.  5‐HT3 receptors promote colonic inflammation via activation of substance P/neurokinin‐1 receptors in dextran sulphate sodium‐induced murine colitis , 2016, British journal of pharmacology.

[28]  D. Angus,et al.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. , 2016, American journal of respiratory and critical care medicine.

[29]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[30]  Dong Han,et al.  Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis. , 2015, International immunopharmacology.

[31]  David T. Huang,et al.  A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators , 2015, Intensive Care Medicine.

[32]  M. Kondo,et al.  Therapeutic action of 5‐HT3 receptor antagonists targeting peritoneal macrophages in post‐operative ileus , 2015, British journal of pharmacology.

[33]  O. Cremer,et al.  Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review , 2014, Critical Care.

[34]  Deepali Gupta,et al.  Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression , 2014, Acta Pharmacologica Sinica.

[35]  Y. Finkelstein,et al.  Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. , 2014, Annals of emergency medicine.

[36]  Hassane Njimi,et al.  Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. , 2014, The Lancet. Respiratory medicine.

[37]  R. Bellomo,et al.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. , 2014, JAMA.

[38]  P. Mahzouni,et al.  Involvement of 5HT3 Receptors in Anti-Inflammatory Effects of Tropisetron on Experimental TNBS-Induced Colitis in Rat. , 2013, BioImpacts : BI.

[39]  H. Svanström,et al.  Ondansetron in pregnancy and risk of adverse fetal outcomes. , 2013, The New England journal of medicine.

[40]  T. Lagu,et al.  Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 , 2012, Critical care medicine.

[41]  T. Kuwaki,et al.  Experimental examination of anti-inflammatory effects of a 5-HT3 receptor antagonist, tropisetron, and concomitant effects on autonomic nervous function in a rat sepsis model. , 2011, International immunopharmacology.

[42]  K. Mousavizadeh,et al.  Granisetron ameliorates acetic acid-induced colitis in rats , 2010, Human & experimental toxicology.

[43]  C. Funck-Brentano,et al.  Droperidol and Ondansetron-induced QT Interval Prolongation: A Clinical Drug Interaction Study , 2008, Anesthesiology.

[44]  H. Medina-Franco,et al.  Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. , 2006, Archives of surgery.

[45]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[46]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[47]  John W. Wilson,et al.  A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. , 2002, American journal of respiratory and critical care medicine.

[48]  L. Färber,et al.  Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics , 2002, Scandinavian journal of rheumatology.

[49]  T. Müller,et al.  The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia? , 2000, Scandinavian journal of rheumatology. Supplement.

[50]  Jacques Duranteau,et al.  Oxidative stress and endothelial dysfunction during sepsis. , 2011, Frontiers in bioscience.